Novel Digital Application for Patients With Acute Leukemia
Recruiting now · Not applicable
Conditions studied: Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
In brief
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
Key facts
- Study ID
- NCT06472128
- Run by
- Massachusetts General Hospital
- People needed
- 200
- Starts
- 2024-10-21
- Expected to finish
- 2030-04-30
- Last updated by the study team
- 2025-11-10
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Hospitalized patients (age > 18 years) with a diagnosis of AML.
- Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +/- additional agents or modification of this regimen on a clinical trial.
- Ability to comprehend and speak English as the digital apps are only available in English
- Note: Patients newly diagnosed as well as those with relapsed/refractory AML initiating treatment with intensive or HMA-based chemotherapy will be eligible to participate.
You may not qualify if…
- Patients with a diagnosis of acute promyelocytic leukemia
- Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.
Where it is running
- Massachusetts General Hospital (MGH) — Boston, Massachusetts, United States (enrolling)
- Duke University — Durham, North Carolina, United States
- Fred Hutchinson Cancer Research Center (FHCRC) — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.